Alvogen Pharma US, Inc. -- Moody's: Alvogen's product acquisition credit positive-- B3 rating unaffected

New York, November 05, 2013 -- Moody's Investors Service commented that Alvogen Pharma US, Inc's ("Alvogen") proposed acquisition of two pharmaceutical products is credit positive because it will increase EBITDA and cash flow and immediately reduce leverage. However, leverage will likely increase back to pre-acquisitions levels in mid-2014 when one of the acquired products loses patent protection. As a result, there is no change to the B3 Corporate Family Rating or the B3 rating on the senior secured term loan. Please go to www.moodys.com for our full Issuer Comment.

Vollständigen Artikel bei Moodys lesen